Clinical characteristics of COVID-19 patients with underlying rheumatic diseases in Japan: data from a multicenter observational study using the COVID-19 Global Rheumatology Alliance physician-reported registry.

"Declarations Conflict of interestMK and JA both are employed by Pharmaceuticals and Medical Devices Agency. The views expressed in this article are those of the authors and do not necessarily reflect the official views of Pharmaceuticals and Medical Devices Agency. TS has received research grants and/or honoraria from Abbvie Japan Co., Ltd., AsahiKASEI Co., Ltd., Astellas Pharma Inc., Ayumi Pharmaceutical, Bristol Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo., Eli Lilly Japan K.K., Mitsubishi-Tanabe Pharma Co., Ono Pharmaceutical, Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., and UCB Japan Co. Ltd. Tokyo Medical and Dental University received unrestricted research grants for Department of Lifetime Clinical Immunology from AbbVie GK, Asahikasei Pharmaceutical Co., AYUMI Pharmaceutical Corporation, Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Japan Blood Products Organization, Nippon Kayaku Co., Ltd. and UCB Japan Co. Ltd. SM received consultant fees/speakers fees from Asahikasei Pharma Corp., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Astellas Pharma Inc. TN received grant/research support from Chugai Pharmaceutical Co., Eisai Co., Ltd., Teijin Pharma Ltd., Eli Lilly Japan K.K., Bristol-Myers K.K., Ono Pharmaceutical Co., Ltd., Asahikasei Pharma Corp., Mitsubishi-Tanabe Pharma Co., Ayumi Pharmaceutical Corporation, Shionogi & Co., Ltd., Sanofi K.K., Nippon Kayaku Co., Ltd., AbbVie GK, Nippon Boehringer Ingelheim Co., Ltd., and Taisho Pharmaceutical Co., Ltd., and consultant fees/speakers fees from UCB Japan Co., Ltd., Eisai Co., Ltd., Chugai Pharmaceutical Co., Astellas Pharma Inc., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Asahikasei Pharma Corp., Eli Lilly Japan K.K., Takeda Pharmaceutical Co., Nippon Boehringer Ingelheim Co., Ltd., AbbVie GK., Taisho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., GlaxoSmithKline plc., Kyowa Kirin Co., Ltd., and Mylan N.V. All other co-authors have nothing to declare. Conflict of interest MK and JA both are employed by Pharmaceuticals and Medical Devices Agency. The views expressed in this article are those of the authors and do not necessarily reflect the official views of Pharmaceuticals and Medical Devices Agency. TS has received research grants and/or honoraria from Abbvie Japan Co., Ltd., AsahiKASEI Co., Ltd., Astellas Pharma Inc., Ayumi Pharmaceutical, Bristol Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo., Eli Lilly Japan K.K., Mitsubishi-Tanabe Pharma Co., Ono Pharmaceutical, Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., and UCB Japan Co. Ltd. Tokyo Medical and Dental University received unrestricted research grants for Department of Lifetime Clinical Immunology from AbbVie GK, Asahikasei Pharmaceutical Co., AYUMI Pharmaceutical Corporation, Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Japan Blood Products Organization, Nippon Kayaku Co., Ltd. and UCB Japan Co. Ltd. SM received consultant fees/speakers fees from Asahikasei Pharma Corp., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Astellas Pharma Inc. TN received grant/research support from Chugai Pharmaceutical Co., Eisai Co., Ltd., Teijin Pharma Ltd., Eli Lilly Japan K.K., Bristol-Myers K.K., Ono Pharmaceutical Co., Ltd., Asahikasei Pharma Corp., Mitsubishi-Tanabe Pharma Co., Ayumi Pharmaceutical Corporation, Shionogi & Co., Ltd., Sanofi K.K., Nippon Kayaku Co., Ltd., AbbVie GK, Nippon Boehringer Ingelheim Co., Ltd., and Taisho Pharmaceutical Co., Ltd., and consultant fees/speakers fees from UCB Japan Co., Ltd., Eisai Co., Ltd., Chugai Pharmaceutical Co., Astellas Pharma Inc., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Asahikasei Pharma Corp., Eli Lilly Japan K.K., Takeda Pharmaceutical Co., Nippon Boehringer Ingelheim Co., Ltd., AbbVie GK., Taisho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., GlaxoSmithKline plc., Kyowa Kirin Co., Ltd., and Mylan N.V. All other co-authors have nothing to declare."

"Declarations: Conflict of interestMK and JA both are employed by Pharmaceuticals and Medical Devices Agency. The views expressed in this article are those of the authors and do not necessarily reflect the official views of Pharmaceuticals and Medical Devices Agency. TS has received research grants and/or honoraria from Abbvie Japan Co., Ltd., AsahiKASEI Co., Ltd., Astellas Pharma Inc., Ayumi Pharmaceutical, Bristol Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo., Eli Lilly Japan K.K., Mitsubishi-Tanabe Pharma Co., Ono Pharmaceutical, Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., and UCB Japan Co. Ltd. Tokyo Medical and Dental University received unrestricted research grants for Department of Lifetime Clinical Immunology from AbbVie GK, Asahikasei Pharmaceutical Co., AYUMI Pharmaceutical Corporation, Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Japan Blood Products Organization, Nippon Kayaku Co., Ltd. and UCB Japan Co. Ltd. SM received consultant fees/speakers fees from Asahikasei Pharma Corp., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Astellas Pharma Inc. TN received grant/research support from Chugai Pharmaceutical Co., Eisai Co., Ltd., Teijin Pharma Ltd., Eli Lilly Japan K.K., Bristol-Myers K.K., Ono Pharmaceutical Co., Ltd., Asahikasei Pharma Corp., Mitsubishi-Tanabe Pharma Co., Ayumi Pharmaceutical Corporation, Shionogi & Co., Ltd., Sanofi K.K., Nippon Kayaku Co., Ltd., AbbVie GK, Nippon Boehringer Ingelheim Co., Ltd., and Taisho Pharmaceutical Co., Ltd., and consultant fees/speakers fees from UCB Japan Co., Ltd., Eisai Co., Ltd., Chugai Pharmaceutical Co., Astellas Pharma Inc., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Asahikasei Pharma Corp., Eli Lilly Japan K.K., Takeda Pharmaceutical Co., Nippon Boehringer Ingelheim Co., Ltd., AbbVie GK., Taisho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., GlaxoSmithKline plc., Kyowa Kirin Co., Ltd., and Mylan N.V. All other co-authors have nothing to declare. Conflict of interest: MK and JA both are employed by Pharmaceuticals and Medical Devices Agency. The views expressed in this article are those of the authors and do not necessarily reflect the official views of Pharmaceuticals and Medical Devices Agency. TS has received research grants and/or honoraria from Abbvie Japan Co., Ltd., AsahiKASEI Co., Ltd., Astellas Pharma Inc., Ayumi Pharmaceutical, Bristol Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo., Eli Lilly Japan K.K., Mitsubishi-Tanabe Pharma Co., Ono Pharmaceutical, Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., and UCB Japan Co. Ltd. Tokyo Medical and Dental University received unrestricted research grants for Department of Lifetime Clinical Immunology from AbbVie GK, Asahikasei Pharmaceutical Co., AYUMI Pharmaceutical Corporation, Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Japan Blood Products Organization, Nippon Kayaku Co., Ltd. and UCB Japan Co. Ltd. SM received consultant fees/speakers fees from Asahikasei Pharma Corp., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Astellas Pharma Inc. TN received grant/research support from Chugai Pharmaceutical Co., Eisai Co., Ltd., Teijin Pharma Ltd., Eli Lilly Japan K.K., Bristol-Myers K.K., Ono Pharmaceutical Co., Ltd., Asahikasei Pharma Corp., Mitsubishi-Tanabe Pharma Co., Ayumi Pharmaceutical Corporation, Shionogi & Co., Ltd., Sanofi K.K., Nippon Kayaku Co., Ltd., AbbVie GK, Nippon Boehringer Ingelheim Co., Ltd., and Taisho Pharmaceutical Co., Ltd., and consultant fees/speakers fees from UCB Japan Co., Ltd., Eisai Co., Ltd., Chugai Pharmaceutical Co., Astellas Pharma Inc., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Asahikasei Pharma Corp., Eli Lilly Japan K.K., Takeda Pharmaceutical Co., Nippon Boehringer Ingelheim Co., Ltd., AbbVie GK., Taisho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., GlaxoSmithKline plc., Kyowa Kirin Co., Ltd., and Mylan N.V. All other co-authors have nothing to declare."